Commentary|Videos|December 12, 2024
Unveiling the Latest in HER2+ Breast Cancer and Beyond With Drs Sara Hurvitz and Neil Iyengar
Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.
Advertisement
Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.
Advertisement
Related to this article
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.
Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Advertisement
Advertisement
Trending on OncLive
1
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
2
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
3
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
4
Dr Forde on Selecting Neoadjuvant and Perioperative Immunotherapy in Resectable NSCLC
5